ELMIND CAPITAL LP
Q4 2025 Form 13-F
NEW YORK, DELAWARE
CIK 0002052213
· CRD 333910
· SEC-registered investment adviser
$338.9M Reported Value Total
ELMIND CAPITAL LP reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $613,614,919, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
1 fund
· $613.6M gross asset value
Hedge Fund: $613.6M
Source: Form ADV filed 2026-09-03
Reported value
$338.9M
Quarter over quarter
0.0%
Holdings
34
Top-10 concentration
68.6%
Key People
Form ADV owners & control persons
Lihan Sun
CHIEF INVESTMENT OFFICER AND LIMITED PARTNER
Ernest Joseph Verrico
CHIEF OPERATING OFFICER, CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2025 13F record
Q4 2025 13F filing summary
| Period of report | December 31, 2025 |
|---|---|
| Filed | February 17, 2026 |
| Form | 13F-HR |
| Reported value | $338.9M |
| Positions | 34 |
| Change in reported value | First reported quarter |
| Top-10 concentration | 68.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
30 | $403.8M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
35 | $398.0M |
|
Q1 2026 13F
Filed May 15, 2026
|
34 | $352.2M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
34 | $338.9M |
Top 20 holdings · Q4 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | COGT COGENT BIOSCIENCES INC | $41.6M | 12.27% |
| 2 | SNDX SYNDAX PHARMACEUTICALS INC | $39.0M | 11.5% |
| 3 | VRDN VIRIDIAN THERAPEUTICS INC | $26.7M | 7.89% |
| 4 | VERA VERA THERAPEUTICS INC | $24.4M | 7.21% |
| 5 | CLDX CELLDEX THERAPEUTICS INC NEW | $23.5M | 6.93% |
| 6 | CGON CG ONCOLOGY INC | $20.4M | 6.03% |
| 7 | BCRX BIOCRYST PHARMACEUTICALS INC | $16.8M | 4.95% |
| 8 | PCVX VAXCYTE INC | $13.4M | 3.97% |
| 9 | BEAM BEAM THERAPEUTICS INC | $13.2M | 3.9% |
| 10 | PHVS PHARVARIS N V | $13.2M | 3.9% |
| 11 | KALV KALVISTA PHARMACEUTICALS INC | $12.9M | 3.82% |
| 12 | DVAX DYNAVAX TECHNOLOGIES CORP | $10.5M | 3.09% |
| 13 | TYRA TYRA BIOSCIENCES INC | $9.2M | 2.72% |
| 14 | NRIX NURIX THERAPEUTICS INC | $8.7M | 2.58% |
| 15 | WVE WAVE LIFE SCIENCES LTD | $7.6M | 2.25% |
| 16 | MBX MBX BIOSCIENCES INC | $6.7M | 1.96% |
| 17 | KRYS KRYSTAL BIOTECH INC | $5.4M | 1.6% |
| 18 | UTHR UNITED THERAPEUTICS CORP DEL | $5.4M | 1.58% |
| 19 | BMRN BIOMARIN PHARMACEUTICAL INC | $4.9M | 1.44% |
| 20 | RLAY RELAY THERAPEUTICS INC | $4.5M | 1.34% |
Values as reported on the Q4 2025 Form 13F. Every position is in the holdings table below.